SCHEMBL23218208

SCHEMBL23218208

OCc1coc2c(CN3CCOCC3)cc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
MAPT P10636 4/20 0.42
HSD17B10 Q99714 4/20 0.42
KDM4E B2RXH2 4/20 0.42
HPGD P15428 2/20 0.42
KLK7 P49862 2/20 0.42
CYP2A13 Q16696 4/20 0.41
CYP2C9 P11712 2/20 0.41
ALOX15 P16050 1/20 0.41
CCR5 P51681 1/20 0.40
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592535 1.00 ALDH1A1 (0.42) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL23218220 0.84 DRD2 (0.38) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL23218342 0.79 DRD2 (0.34)
SCHEMBL23218308 0.78 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EPOLBHTT
SCHEMBL29591485 0.78 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EPOLBHTT
SCHEMBL29852611 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHSD17B10KDM4EALOX15
SCHEMBL23219165 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHSD17B10KDM4EALOX15
SCHEMBL29852890 0.77 MMP1 (0.44) KMT2AMEN1
SCHEMBL23218203 0.77 MMP1 (0.44) KMT2AMEN1
SCHEMBL23218980 0.75 PTPN1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALDH1A1 2667/4885MAPT 4793/4885HSD17B10 1149/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3142/4885MAPT 3561/4885HSD17B10 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.